Catalog Products » PSCA hFc Chimera, Human
Manual
Manual
COAs

PSCA hFc Chimera, Human

Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
$390.00
Z05771-100

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc PSCA (Leu12-Ser86)_x000D_
Accession # O43653
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 34.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

PSCA HFc Chimera, Human

Immobilized PSCA hFc Chimera, Human, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-PSCA Antibody, hFc-Avi Tag with the EC50 of 85.0ng/ml determined by ELISA. »

PSCA HFc Chimera, Human

The purity of PSCA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

PSCA HFc Chimera, Human

PSCA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
Synonyms PSCA; UNQ206; PRO232
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.